Spinal Cord Stimulation (SCS) Implantable Pulse Generator (IPG)
ABBOTT MEDICAL · Decision date Oct 30, 2026
What did the FDA decide?
FDA posted a 30-day notice for PMA supplement P010032/S266, dated 2026-10-30, with decision OK30. The supplement reason is a process change involving manufacturer, sterilizer, packager, or supplier. The stated change is from an animal-derived to a non-animal-derived EBS lubricant used in TPU resin production for the BLE antenna manufacturing process.
The statement specifies that this applies to the BLE antenna used in the implantable pulse generator for either bundled device: the deep brain stimulator and the spinal cord stimulator. The device category is a totally implanted spinal-cord stimulator for pain relief, product code LGW, with Abbott Medical as the applicant. The source does not state whether the change affects device safety or performance.
FDA approval order statement
animal-derived to non-animal derived EBS [Ethylene Bis-stearamide] lubricant to be used in TPU [thermoplastic polyurethane] resin production for the BLE [Bluetooth low energy] antenna manufacturing process. This applies specifically to the BLE antenna used in the IPG [implantable pulse generator] for either bundled device; DBS [Deep Brain Stimulator] and SCS [Spinal cord Stimulator]
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Neurology
- Decision date
- Oct 30, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P010032/S266
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- LGW
- Decision code
- OK30
- Decision date
- Oct 30, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, spinal-cord, totally implanted for pain relief.
- Applicant
- Abbott Medical
- Product code
- LGW
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P010032. Subsequent supplements may change the device or its indications.
FDA decision timeline
P010032 · Original PMA
GENESIS AND EON FAMILY NEUROSTIMULATION (IPG) SYSTEMS
P010032/S261 · Related supplement
Spinal Cord Stimulation (SCS) Implantable Pulse Generator (IPG) Charger
P010032/S251 · Related supplement
Quattrode; Octrode; Penta; Lamitrode; Tripole; TriCentrus Lead Extensions
P010032/S260 · Related supplement
Proclaim family of SCS IPG
P010032/S266 received
Application receipt date recorded by FDA.
P010032/S265 · Related supplement
Eterna Spinal Cord Stimulation (SCS) Implantable Pulse Generator
P010032/S262 · Related supplement
Spinal Cord Stimulation (SCS) External Pulse Generator (EPG)
P010032/S264 · Related supplement
Spinal Cord Stimulation (SCS) Implantable Pulse Generator (IPG) Charger
P010032/S266 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P010032. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P010032
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA approval | Nov 21, 2001 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Sep 11, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Sep 18, 2026 | FDA | |
Proclaim family of SCS IPGP010032/S260 | ABBOTT MEDICAL | PMA supplement | Sep 23, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | Oct 27, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 28, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA |
Explore the linked device profile
Other records with product code LGW
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Neuromodulation | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 29, 2026 | FDA | |
Saluda Medical Evoke SCS SystemP190002/S052 | Saluda Medical Pty, Ltd. | PMA supplement | Oct 16, 2026 | FDA |
Saluda Medical Evoke SCS SystemP190002/S051 | Saluda Medical Pty, Ltd. | PMA supplement | Oct 15, 2026 | FDA |
| Medtronic Neuromodulation | PMA supplement | Oct 6, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 6901 Preston Rd., Plano, TX, 75024
Sources and methodology
- Original FDA record: P010032/S266
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records






